Lolium perenne peptide immunotherapy is well tolerated and elicits a protective B‐cell response in seasonal allergic rhinitis patients

BACKGROUND: Systemic allergic reactions are a risk for allergen immunotherapy that utilizes intact allergen preparations. We evaluated the safety, efficacy and immune mechanisms of short‐course treatment with adjuvant‐free Lolium perenne peptides (LPP) following a 6‐week dose‐escalation protocol. ME...

Descripción completa

Detalles Bibliográficos
Autores principales: Mösges, R., Koch, A. F., Raskopf, E., Singh, J., Shah‐Hosseini, K., Astvatsatourov, A., Hauswald, B., Yarin, Y., Corazza, F., Haazen, L., Pirotton, S., Allekotte, S., Zadoyan, G., Legon, T., Durham, S. R., Shamji, M. H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6032848/
https://www.ncbi.nlm.nih.gov/pubmed/29322510
http://dx.doi.org/10.1111/all.13392

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6032848/
https://www.ncbi.nlm.nih.gov/pubmed/29322510
http://dx.doi.org/10.1111/all.13392

Ejemplares similares